Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology
- 주제(키워드) oncology , value frameworks , country adaptation
- 주제(기타) Environmental Sciences
- 주제(기타) Public, Environmental & Occupational Health
- 설명문(일반) [Bae, Green; Bae, SeungJin; Han, Juhee] Ewha Womans Univ, Coll Pharm, Seoul 03760, South Korea; [Lee, Donghwan] Ewha Womans Univ, Dept Stat, Seoul 03760, South Korea; [Koo, Dong-Hoe] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Div Hematol Oncol,Sch Med, Seoul 03063, South Korea; [Kim, Do Yeun] Dongguk Univ, Dept Internal Med, Div Hematol Oncol, Ilsan Hosp, Seoul 10326, South Korea; [Kim, Hee-Jun] Chung Ang Univ Hosp, Dept Internal Med, Div Hematol Med Oncol, Seoul 06974, South Korea; [Oh, Sung Young] Dong A Univ, Dept Internal Med, Dong A Univ Hosp, Coll Med, Busan 49236, South Korea; [Lee, Hee Yeon] Catholic Univ Korea, Dept Internal Med, Div Oncol, Yeouido St Marys Hosp, Seoul 07345, South Korea; [Lee, Jong Hwan] Dept Pharmaceut Benefits Hlth Insurance Review &, Wonju 26465, South Korea; [Han, Hye Sook] Chungbuk Natl Univ, Coll Med, Dept Internal Med, Cheongju 28644, South Korea; [Ha, Hyerim] Inha Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Incheon 400711, South Korea; [Kang, Jin Hyoung] Catholic Univ Korea, Seoul St Marys Hosp, Med Oncol, Seoul 07345, South Korea
- 등재 SCIE, SSCI, SCOPUS
- 발행기관 MDPI
- 발행년도 2021
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000181521
- 본문언어 영어
- Published As http://dx.doi.org/10.3390/ijerph18063139
초록/요약
This study sought to adapt the existing value framework (VF) to produce a reliable and valid Korean oncology VF. Two VFs developed by The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) were selected for examination in the present study. Forward and backward translations were conducted for six high-priced drugs indicated for non-small-cell lung cancer and multiple myeloma. Inter-rater reliability was measured based on the intraclass correlation coefficient (ICC) and variation was described using the coefficient of variation. The relative weights of factors critically considered by Korean oncologists were derived following the analytic hierarchy process (AHP), and focus group interviews (FGIs) were used to obtain qualitative data regarding the applications of these two VFs in the Korean setting. The ICCs of the Korean VFs were 0.895 (0.654-0.983) for ASCO and 0.726 (0-0.982) for ESMO translations, suggesting excellent reliability for ASCO and good reliability for ESMO. AHP demonstrated that clinical benefit has the highest priority, which is consistent with the ASCO VF. The FGIs suggested that the result for AHP is acceptable and that both ESMO and ASCO VFs should be used complementarily. Although further evaluation with a larger sample size is needed, the Korean versions of ESMO/ASCO VFs are valid and reliable tools and are acceptable to Korean stakeholders, yet they should be applied with caution.
more